Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis

References

• Wang C, Wang B, Hou S, et al. Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer. Eur J Med Chem. 2019;163:787–803.
   PubMed Web of Science ®Google Scholar
• Ben-Sahra I, Puissant A. HER2 signaling hijacks the creatine shuttle to fuel breast cancer cell growth. Cell Metab. 2018;28(6):805–807.
   PubMed Web of Science ®Google Scholar
• Marusiak AA, Prelowska MK, Mehlich D, et al. Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. Oncogene. 2019;38(15):2860–2875.
   PubMed Web of Science ®Google Scholar
• Cao H, Dan Z, He X, et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano. 2016;10(8):7738–7748.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Rubio IT, Klaase JM, et al. Surgical treatment of nonpalpable primary invasive and in situ breast cancer. Nat Rev Clin Oncol. 2015;12(11):645–663.
   PubMed Web of Science ®Google Scholar
• Zacharakis N, Chinnasamy H, Black M, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724–730.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Barlow WE, Albain KS, et al. Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. N Engl J Med. 2019;380(13):1226–1234.
   PubMed Web of Science ®Google Scholar
• Murthy R, Borges VF, Conlin A, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(7):880–888.
   PubMed Web of Science ®Google Scholar
• Chen Y, Keskin D, Sugimoto H, et al. Podoplanin + tumor lymphatics are rate limiting for breast cancer metastasis. PLoS Biol. 2018;16(12):e2005907.
   PubMed Web of Science ®Google Scholar
• Jiang WG, Sanders AJ, Katoh M, et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol. 2015;35:S244–S275.
   PubMed Web of Science ®Google Scholar
• Pilewskie M, Morrow M. Margins in breast cancer: how much is enough? Cancer. 2018;124(7):1335–1341.
   PubMed Web of Science ®Google Scholar
• Reggiani F, Labanca V, Mancuso P, et al. Adipose progenitor cell secretion of GM-CSF and MMP9 promotes a stromal and immunological microenvironment that supports breast cancer progression. Cancer Res. 2017;77(18):5169–5182.
   PubMed Web of Science ®Google Scholar
• Bai J, Yeh S, Qiu X, et al. TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR490-3p/vimentin signals. Oncogene. 2018;37(44):5901–5912.
   PubMed Web of Science ®Google Scholar
• Boudria A, Abou Faycal C, Jia T, et al. VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a beta1 integrin/VEGFR autocrine loop. Oncogene. 2019;38(7):1050–1066.
   PubMed Web of Science ®Google Scholar
• Tasdemir N, Bossart EA, Li Z, et al. Comprehensive phenotypic characterization of human invasive lobular carcinoma cell lines in 2D and 3D cultures. Cancer Res. 2018;78(21):6209–6222.
   PubMed Web of Science ®Google Scholar
• Yang F, Takagaki Y, Yoshitomi Y, et al. Inhibition of dipeptidyl peptidase-4 accelerates epithelial–mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis. Cancer Res. 2019;79(4):735–746.
   PubMed Web of Science ®Google Scholar
• Wang X, Cheng L, Xie H-J, et al. Functional paclitaxel plus honokiol micelles destroying tumour metastasis in treatment of non-small-cell lung cancer. Artif Cells Nanomed Biotechnol. 2018;46(Suppl. 2):1154–1169.
   PubMedGoogle Scholar
• Liu Y, Li F, Yang YT, et al. IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma. Oncogene. 2019;38(11):1815–1831.
   PubMed Web of Science ®Google Scholar
• Kim K-J, Kwon S-H, Yun J-H, et al. STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression. Oncogene. 2017;36(39):5445–5459.
   PubMed Web of Science ®Google Scholar
• Liu J-J, Tang W, Fu M, et al. Development of R8 modified epirubicin-dihydroartemisinin liposomes for treatment of non-small-cell lung cancer. Artif Cells Nanomed Biotechnol. 2019;47(1):1947–1960.
   PubMed Web of Science ®Google Scholar
• Song X-l, Ju R-j, Xiao Y, et al. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer. Int J Nanomedicine. 2017;12:7433–7451.
   PubMed Web of Science ®Google Scholar
• Wan Y, Wang L, Zhu C, et al. Aptamer-conjugated extracellular nanovesicles for targeting drug delivery. Cancer Res. 2018;78(3):798–808.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang Q, Bao J, et al. Schisandrin B suppresses glioma cell metastasis mediated by inhibition of mTOR/MMP-9 signal pathway. Biomed Pharmacother. 2015;74:77–82.
   PubMed Web of Science ®Google Scholar
• Cai D, Gao W, He B, et al. Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials. 2014;35(7):2283–2294.
   PubMed Web of Science ®Google Scholar
• Kalmouni M, Al-Hosani S, Magzoub M. Cancer targeting peptides. Cell Mol Life Sci. 2019;76(11):2171–2183.
   PubMed Web of Science ®Google Scholar
• Watkins CL, Brennan P, Fegan C, et al. Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. J Control Release. 2009;140(3):237–244.
   PubMed Web of Science ®Google Scholar
• Lakkadwala S, Singh J. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model. Colloids Surf B Biointerfaces. 2019;173:27–35.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fu M, Liu J, et al. Inhibition of tumor metastasis by targeting daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer. Int J Nanomed. 2019;14:4071–4090.
   PubMed Web of Science ®Google Scholar
• Li X-T, Zhou Z-Y, Jiang Y, et al. PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer. J Drug Target. 2015;23(3):232–243.
   PubMed Web of Science ®Google Scholar
• Meng J, Chen S, Lei Y-y, et al. Hsp90beta promotes aggressive vasculogenic mimicry via epithelial–mesenchymal transition in hepatocellular carcinoma. Oncogene. 2019;38(2):228–243.
   PubMed Web of Science ®Google Scholar
• DeBord LC, Pathak RR, Villaneuva M, et al. The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research. Am J Cancer Res. 2018;8(8):1642–1660.
   PubMed Web of Science ®Google Scholar
• Yue Y, Zhao D, Yin Q. Hyaluronic acid modified nanostructured lipid carriers for transdermal bupivacaine delivery: in vitro and in vivo anesthesia evaluation. Biomed Pharmacother. 2018;98:813–820.
   PubMed Web of Science ®Google Scholar
• Ireland L, Santos A, Campbell F, et al. Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. Oncogene. 2018;37(15):2022–2036.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Suman VJ, Reid JM, et al. First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer. J Clin Oncol. 2017;35(30):3391–3400.
   PubMed Web of Science ®Google Scholar
• Mu L-M, Ju R-J, Liu R, et al. Dual-functional drug liposomes in treatment of resistant cancers. Adv Drug Deliv Rev. 2017;115:46–56.
   PubMed Web of Science ®Google Scholar
• Mauceri A, Giansanti L, Bozzuto G, et al. Structurally related glucosylated liposomes: correlation of physicochemical and biological features. Biochim Biophys Acta Biomembr. 2019;1861(8):1468–1475.
   PubMed Web of Science ®Google Scholar
• Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3–6.
   PubMed Web of Science ®Google Scholar
• Mendez O, Peg V, Salvans C, et al. Extracellular HMGA1 promotes tumor invasion and metastasis in triple-negative breast cancer. Clin Cancer Res. 2018;24(24):6367–6382.
   PubMed Web of Science ®Google Scholar
• Bai J, Wu K, Cao M-H, et al. SCFFBXO22 targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis. Proc Natl Acad Sci USA. 2019;116(24):11754–11763.
   PubMed Web of Science ®Google Scholar
• Li J, Lu Y, Wang D, et al. Schisandrin B prevents ulcerative colitis and colitis-associated-cancer by activating focal adhesion kinase and influence on gut microbiota in an in vivo and in vitro model. Eur J Pharmacol. 2019;854:9–21.
   PubMed Web of Science ®Google Scholar
• Delgado-Bellido D, Fernández-Cortés M, Rodríguez MI, et al. VE-cadherin promotes vasculogenic mimicry by modulating kaiso-dependent gene expression. Cell Death Differ. 2019;26(2):348–361.
   PubMed Web of Science ®Google Scholar
• Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24(21):5233–5238.
   PubMed Web of Science ®Google Scholar
• Yun Y, Gao R, Yue H, et al. Sulfate aerosols promote lung cancer metastasis by epigenetically regulating the epithelial-to-mesenchymal transition (EMT). Environ Sci Technol. 2017;51(19):11401–11411.
   PubMed Web of Science ®Google Scholar
• McKay RR, Bossé D, Gray KP, et al. Radium-223 dichloride in combination with vascular endothelial growth factor-targeting therapy in advanced renal cell carcinoma with bone metastases. Clin Cancer Res. 2018;24(17):4081–4088.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Xin H, Han T. BECN1 promotes the migration of NSCLC cells through regulating the ubiquitination of vimentin. Cell Adh Migr. 2019;13(1):249–259.
   PubMed Web of Science ®Google Scholar
• Dong H, Diao H, Zhao Y, et al. Overexpression of matrix metalloproteinase-9 in breast cancer cell lines remarkably increases the cell malignancy largely via activation of transforming growth factor beta/SMAD signalling. Cell Prolif. 2019;52:e12633.
   PubMed Web of Science ®Google Scholar